Medscape3d
Ipratropium bromide nasal spray in non-allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life.
This study evaluates a new aqueous nasal formulation of ipratropium bromide (Atrovent Nasal Spray 0.03%) in subjects with perennial non-allergic rhinitis in a double-blind, placebo-controlled trial.
Monthly Prescribing Reference3y
Ipratropium Nasal Spray 0.06%
Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...
Medscape1y
Cardiovascular Events Associated with Ipratropium Bromide in COPD
Background: Studies have suggested an increased risk of cardiovascular morbidity and mortality associated with the use of ipratropium bromide. We sought to examine the association between ...
Monthly Prescribing Reference3y
Ipratropium Nasal Spray 0.03%
Ipratropium bromide 0.03% (21mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...